- Home
- CRBU vs GNLX Comparison
CRBU vs GNLX Comparison
Compare CRBU & GNLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRBU
- GNLX
- Stock Information
- Founded
- CRBU 2011
- GNLX 2001
- Country
- CRBU United States
- GNLX United States
- Employees
- CRBU N/A
- GNLX N/A
- Industry
- CRBU Medicinal Chemicals and Botanical Products
- GNLX Biotechnology: Pharmaceutical Preparations
- Sector
- CRBU Health Care
- GNLX Health Care
- Exchange
- CRBU Nasdaq
- GNLX Nasdaq
- Market Cap
- CRBU 93.0M
- GNLX 109.4M
- IPO Year
- CRBU 2021
- GNLX 2023
- Fundamental
- Price
- CRBU $1.62
- GNLX $3.08
- Analyst Decision
- CRBU Strong Buy
- GNLX Strong Buy
- Analyst Count
- CRBU 4
- GNLX 4
- Target Price
- CRBU $8.50
- GNLX $17.75
- AVG Volume (30 Days)
- CRBU 1.9M
- GNLX 155.2K
- Earning Date
- CRBU 08-05-2025
- GNLX 08-13-2025
- Dividend Yield
- CRBU N/A
- GNLX N/A
- EPS Growth
- CRBU N/A
- GNLX N/A
- EPS
- CRBU N/A
- GNLX N/A
- Revenue
- CRBU $9,918,000.00
- GNLX N/A
- Revenue This Year
- CRBU $9.52
- GNLX N/A
- Revenue Next Year
- CRBU N/A
- GNLX N/A
- P/E Ratio
- CRBU N/A
- GNLX N/A
- Revenue Growth
- CRBU N/A
- GNLX N/A
- 52 Week Low
- CRBU $0.66
- GNLX $1.60
- 52 Week High
- CRBU $3.00
- GNLX $5.89
- Technical
- Relative Strength Index (RSI)
- CRBU 70.55
- GNLX 52.03
- Support Level
- CRBU $1.62
- GNLX $2.80
- Resistance Level
- CRBU $1.79
- GNLX $3.61
- Average True Range (ATR)
- CRBU 0.12
- GNLX 0.23
- MACD
- CRBU 0.03
- GNLX 0.02
- Stochastic Oscillator
- CRBU 91.79
- GNLX 38.37
About CRBU Caribou Biosciences Inc.
Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) biopharmaceutical company dedicated to transforming the lives of patients with devastating diseases by applying its novel CRISPR platform, CRISPR hybrid RNA-DNA (chRDNA), toward the development of next-generation, genome-edited cell therapies. The company operates and manage business as one reportable operating segment, which is the business of developing a pipeline of allogeneic CAR-T and CAR-NK cell therapies. Geographically, it operates in United States and Rest of the World, of which United States derives maximum revenue.
About GNLX Genelux Corporation
Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec), Lung, and Pancreatic Cancer.